| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shalini Rahul Purwar Appointed as Whole-time director since October 2018 | Whole-time director | 08-Oct-2018 | Current |
Atharva Ajay Karulkar Appointed as Director since October 2021 | Director | 29-Oct-2021 | Current |
Rahul Purwar Appointed as Director since October 2018 | Director | 08-Oct-2018 | Current |
Ravindranath Kancherla Appointed as Nominee Director since December 2021 | Nominee Director | 09-Dec-2021 | Current |
Satyanarayana Chava Appointed as Nominee Director since December 2021 | Nominee Director | 09-Dec-2021 | Current |
Shirish Arya Appointed as Director since August 2021 | Director | 06-Aug-2021 | Current |
Premium access Complete director detailsUnlock the complete director and KMP records available for Immunoadoptive Cell Therapy Private Limited.
Verified entity values are shown only after access is granted. | |||
People Timeline
Explore the timeline of key personnel in Immunoadoptive Cell Therapy Private Limited's leadership journey.
Loading...
Contact Details
- Address Plot No.D-222/26,Ttc Industrial Area, Midc,Village Shiravane,Navi Mumbai, Thane Maharashtra, 400706, India
- Telephone Upgrade
- Email Upgrade
- Pin Code 400706
- Country India
- Website immunoact.com
- Social Media
Frequently Asked Questions
You can contact Immunoadoptive Cell Therapy Private Limited through their registered address at Plot No.D-222/26,Ttc Industrial Area, Midc,Village Shiravane,Navi Mumbai, Thane Maharashtra, 400706, India, or via their website at immunoact.com. Social media links are also provided where applicable.
The current directors of Immunoadoptive Cell Therapy Private Limited are listed above in the "Current Directors & Signatories" section. You can view their names, designations, and appointment dates.
- RAHUL PURWAR
- SHALINI RAHUL PURWAR
- SATYANARAYANA CHAVA
- RAVINDRANATH KANCHERLA
- SHIRISH ARYA
- ATHARVA AJAY KARULKAR
Past director details are available under the "Past Directors & Signatories" tab. You may need to upgrade your subscription to view detailed information.